This inventor holds 2 USPTO granted patents. Top assignee: Yoshitomi Pharmaceutical Industries, Ltd.. Active years: 1989-1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Fukuoka, JP (1989)
- Chikujo-gun, JP (1997)
Company Filing History:
Years Active: 1989-1997
Title: Akihiko Moriguchi: Innovator in Antibacterial Compounds
Introduction
Akihiko Moriguchi is a notable inventor based in Chikujo-gun, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents. With a total of 2 patents, his work has the potential to impact the treatment of infectious diseases.
Latest Patents
Moriguchi's latest patents include the development of 8-methoxy-quinolonecarboxylic acid derivatives. These compounds exhibit a wide range of in vitro and in vivo antibacterial effects against Gram-positive bacteria, while also maintaining a strong antibacterial effect against Gram-negative bacteria. The compounds are designed to have minimal side effects and low toxicity, making them promising candidates for clinical use as antibacterial agents. Another significant patent involves quinolonecarboxylic acid compounds, which demonstrate antibacterial activities useful for treating various infectious diseases.
Career Highlights
Moriguchi is currently associated with Yoshitomi Pharmaceutical Industries, Ltd., where he continues to innovate in the field of pharmaceuticals. His research focuses on creating effective antibacterial agents that can address the growing concern of antibiotic resistance.
Collaborations
Moriguchi has collaborated with notable colleagues such as Tsuyoshi Kuroda and Yoshifumi Ikeda. Their combined expertise contributes to the advancement of research in antibacterial compounds.
Conclusion
Akihiko Moriguchi's work in developing novel antibacterial agents showcases his commitment to improving healthcare through innovation. His contributions are expected to have a lasting impact on the treatment of infectious diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile